ARCHIT ORGANOSYS LTD. is a Chemicals & Petrochemicals company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY23 | FY24 |
|---|---|---|
| Revenue | 128 | 113 |
| EBITDA (ex other income) | 21 | 10 |
| margin % | 16.1 | 8.9 |
| Owners' profit | 11 | 3 |
| EPS, as reported (₹) | 5.53 | 1.60 |
| ROE % · ROCE % | 18.4 · 22.4 | 5.1 · 9.3 |
| Debt / equity (x) | 0.50 | 0.40 |
| Cash from operations | 19 | 10 |
| Capex | (16) | (2) |
| ₹ crore | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 |
|---|---|---|---|---|---|---|
| Revenue | 22 | 47 | 31 | 26 | 25 | 31 |
| Profit before tax | 4 | 3 | 2 | 1 | (1) | 2 |
| Net profit | 2 | 2 | 2 | 0 | (0) | 2 |
| EPS (₹) | 1.09 | 0.94 | 0.77 | 0.18 | (0.22) | 0.87 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DEEPAK FERTILIZERS & PETR | 16,727 | 17.0 | 2.24 | 12.2 | 9.9 | 8.4 | 14.6 | 26.1 |
| TATA CHEMICALS LTD | 15,683 | — | 0.71 | 141.2 | (7.7) | (5.0) | 7.4 | 14.4 |
| GUJ NAR VAL FER & CHEM L | 8,273 | 8.0 | 0.91 | 6.0 | 8.9 | 10.3 | 8.7 | 22.1 |
| TANFAC INDUSTRIES LTD. | 6,773 | 55.4 | 18.15 | — | 18.8 | 24.3 | — | 16.0 |
| GUJARAT ALKALIES & CHEM | 5,179 | 78.0 | 1.00 | 10.7 | (0.0) | 0.7 | 12.4 | 18.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Notice of 33rd AGM published in newspapers | compliance | minimal | — | — |
| 7 Sept 2026 · 33rd AGM on 30 Sep 2026; 10% dividend recommended; PAT up 59% YoY | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Archit Organosys FY26 annual report: revenue up 11.8%, profit up 59% | compliance | low | — | — |
| 3 Sept 2026 · Record date fixed for FY26 final dividend | corporate actions | medium | — | — |
| 3 Sept 2026 · Board approves preferential share swap to acquire Archit Life Science | fund raising | high | — | — |
| 3 Sept 2026 · Board hikes authorised capital, approves share swap to acquire Archit Life Science | fund raising | high | — | — |
| 27 Aug 2026 · Board meeting Sept 3 to consider raising funds via equity shares and securities | compliance | minimal | — | — |
| 27 Aug 2026 · Board to consider fund raising via equity securities on 3 Sept 2026 | fund raising | medium | — | — |
| 13 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 12 Aug 2026 · Q1 FY27 Results: Revenue up 12%, net profit down 29% at Rs. 144.70 lakh | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| GHCL LIMITED |
| 3,879 |
| 8.4 |
| 1.09 |
| 5.1 |
| 13.3 |
| 16.6 |
| 1.1 |
| 23.9 |
| GRAUER & WEIL IND LTD | 3,469 | 21.2 | 3.21 | 14.1 | 15.2 | 19.2 | 14.5 | 20.4 |
| J.G.CHEMICALS LIMITED | 2,330 | 31.0 | 4.31 | 23.7 | 12.7 | 16.9 | — | 11.5 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 42.4 | 17.0 | 46 of 57 | 20% |
| P/B | 2.2 | 1.4 | 35 of 59 | 41% |
| ROCE | 5.8 | 6.2 | 34 of 65 | 48% |
| ROE | 5.1 | 4.9 | 32 of 65 | 52% |
| Debt / Equity | 0.4 | 0.2 | 44 of 65 | 33% |
| EBITDA margin | 14.2 | 13.3 | 26 of 58 | 56% |
| Revenue growth | (33.4) | 6.7 | 49 of 54 | 9% |
| Profit growth | (7.6) | 21.0 | 41 of 64 | 37% |
| Market cap | 139 | 77 | 29 of 65 | 56% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
